Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risankizumab - AbbVie/Boehringer Ingelheim

Next Previous
Drug Profile

Risankizumab - AbbVie/Boehringer Ingelheim

Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZI

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Registered Erythrodermic psoriasis; Generalised pustular psoriasis
  • Phase III Palmoplantar pustulosis
  • Phase II Atopic dermatitis; Hidradenitis suppurativa
  • No development reported Unspecified
  • Discontinued Ankylosing spondylitis; Asthma

Most Recent Events

  • 10 Jun 2025 Abbvie plans a phase I pharmacokinetics trial (In volunteers) in June 2025 (SC) (NCT07007091)
  • 08 May 2025 AbbVie initiates a phase-I trial In volunteers (SC), (NCT06946524)
  • 27 Apr 2025 AbbVie plans a phase-I trial In volunteers (SC), (NCT06946524)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top